Mesothelioma Clinical Trials: Are Minorities Underrepresented?
The results of a new study from Harvard and Dana Farber Cancer Institute raise the question of whether ethnic minorities are being fairly represented in mesothelioma clinical trials. The study focused on four of the most common types of cancer in the US: breast, prostate, lung, and colorectal cancer. It looked at demographic data for close to 6,000 people enrolled in precision oncology trials for these cancers. Researchers found that clinical trials tend to favor white and Asian patients over Hispanic and black patients. The study could have implications for mesothelioma clinical trials of new, tailored treatments. Precision Oncology and Mesothelioma Clinical Trials Malignant mesothelioma is a challenging cancer to treat. Mesothelioma cells are good at protecting themselves from damaging…